Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Anesthesiology
2016 Mar 01;1243:651-63. doi: 10.1097/ALN.0000000000000992.
Show Gene links
Show Anatomy links
γ-Aminobutyric Acid Type A Receptor Modulation by Etomidate Analogs.
Pejo E
,
Santer P
,
Wang L
,
Dershwitz P
,
Husain SS
,
Raines DE
.
???displayArticle.abstract???
Etomidate is a highly potent anesthetic agent that is believed to produce hypnosis by enhancing γ-aminobutyric acid type A (GABAA) receptor function. The authors characterized the GABAA receptor and hypnotic potencies of etomidate analogs. The authors then used computational techniques to build statistical and graphical models that relate the potencies of these etomidate analogs to their structures to identify the specific molecular determinants of potency. GABAA receptor potencies were defined with voltage clamp electrophysiology using α1β3γ2 receptors harboring a channel mutation (α1[L264T]) that enhances anesthetic sensitivity (n = 36 to 60 measurements per concentration-response curve). The hypnotic potencies of etomidate analogs were defined using a loss of righting reflexes assay in Sprague Dawley rats (n = 9 to 21 measurements per dose-response curve). Three-dimensional quantitative structure-activity relationships were determined in silico using comparative molecular field analysis. The GABAA receptor and hypnotic potencies of etomidate and the etomidate analogs ranged by 91- and 53-fold, respectively. These potency measurements were significantly correlated (r = 0.72), but neither measurement correlated with drug hydrophobicity (r = 0.019 and 0.005, respectively). Statistically significant and predictive comparative molecular field analysis models were generated, and a pharmacophore model was built that revealed both the structural elements in etomidate analogs associated with high potency and the interactions that these elements make with the etomidate-binding site. There are multiple specific structural elements in etomidate and etomidate analogs that mediate GABAA receptor modulation. Modifying any one element can alter receptor potency by an order of magnitude or more.
Barker,
Activity of CNS depressants related to hydrophobicity.
1974, Pubmed
Barker,
Activity of CNS depressants related to hydrophobicity.
1974,
Pubmed
Belelli,
The in vitro and in vivo enantioselectivity of etomidate implicates the GABAA receptor in general anaesthesia.
2003,
Pubmed
,
Xenbase
Belelli,
The interaction of the general anesthetic etomidate with the gamma-aminobutyric acid type A receptor is influenced by a single amino acid.
1997,
Pubmed
,
Xenbase
Bertaccini,
Assessment of homology templates and an anesthetic binding site within the γ-aminobutyric acid receptor.
2013,
Pubmed
Bu,
Stereoselectivity of isoflurane in adhesion molecule leukocyte function-associated antigen-1.
2014,
Pubmed
Chiara,
Specificity of intersubunit general anesthetic-binding sites in the transmembrane domain of the human α1β3γ2 γ-aminobutyric acid type A (GABAA) receptor.
2013,
Pubmed
Chiara,
Mapping general anesthetic binding site(s) in human α1β3 γ-aminobutyric acid type A receptors with [³H]TDBzl-etomidate, a photoreactive etomidate analogue.
2012,
Pubmed
Cotten,
Methoxycarbonyl-etomidate: a novel rapidly metabolized and ultra-short-acting etomidate analogue that does not produce prolonged adrenocortical suppression.
2009,
Pubmed
,
Xenbase
Cotten,
Carboetomidate: a pyrrole analog of etomidate designed not to suppress adrenocortical function.
2010,
Pubmed
,
Xenbase
Davies,
Modulation by general anaesthetics of rat GABAA receptors comprised of alpha 1 beta 3 and beta 3 subunits expressed in human embryonic kidney 293 cells.
1997,
Pubmed
Desai,
Gamma-amino butyric acid type A receptor mutations at beta2N265 alter etomidate efficacy while preserving basal and agonist-dependent activity.
2009,
Pubmed
,
Xenbase
Forman,
Clinical and molecular pharmacology of etomidate.
2011,
Pubmed
Forman,
Monod-Wyman-Changeux allosteric mechanisms of action and the pharmacology of etomidate.
2012,
Pubmed
Franks,
Structural comparisons of ligand-gated ion channels in open, closed, and desensitized states identify a novel propofol-binding site on mammalian γ-aminobutyric acid type A receptors.
2015,
Pubmed
GODEFROI,
DL-1-(1-ARYLALKYL)IMIDAZOLE-5-CARBOXYLATE ESTERS. A NOVEL TYPE OF HYPNOTIC AGENTS.
1965,
Pubmed
Ge,
The pharmacology of cyclopropyl-methoxycarbonyl metomidate: a comparison with propofol.
2014,
Pubmed
,
Xenbase
Ge,
Pharmacological studies of methoxycarbonyl etomidate's carboxylic acid metabolite.
2012,
Pubmed
,
Xenbase
Gregoret,
Hydrogen bonds involving sulfur atoms in proteins.
1991,
Pubmed
Guitchounts,
Two etomidate sites in α1β2γ2 γ-aminobutyric acid type A receptors contribute equally and noncooperatively to modulation of channel gating.
2012,
Pubmed
,
Xenbase
Hill-Venning,
Subunit-dependent interaction of the general anaesthetic etomidate with the gamma-aminobutyric acid type A receptor.
1997,
Pubmed
,
Xenbase
Husain,
Modifying methoxycarbonyl etomidate inter-ester spacer optimizes in vitro metabolic stability and in vivo hypnotic potency and duration of action.
2012,
Pubmed
Jurd,
General anesthetic actions in vivo strongly attenuated by a point mutation in the GABA(A) receptor beta3 subunit.
2003,
Pubmed
Li,
Identification of a GABAA receptor anesthetic binding site at subunit interfaces by photolabeling with an etomidate analog.
2006,
Pubmed
Pejo,
Analogues of etomidate: modifications around etomidate's chiral carbon and the impact on in vitro and in vivo pharmacology.
2014,
Pubmed
,
Xenbase
Pejo,
In vivo and in vitro pharmacological studies of methoxycarbonyl-carboetomidate.
2012,
Pubmed
,
Xenbase
Peoples,
Inhibition of N-methyl-D-aspartate receptors by straight-chain diols: implications for the mechanism of the alcohol cutoff effect.
2002,
Pubmed
Reynolds,
Sedation and anesthesia mediated by distinct GABA(A) receptor isoforms.
2003,
Pubmed
Rüsch,
Gating allosterism at a single class of etomidate sites on alpha1beta2gamma2L GABA A receptors accounts for both direct activation and agonist modulation.
2004,
Pubmed
,
Xenbase
Sear,
What makes a molecule an anaesthetic? Studies on the mechanisms of anaesthesia using a physicochemical approach.
2009,
Pubmed
Sewell,
Derivation of preliminary three-dimensional pharmacophoric maps for chemically diverse intravenous general anaesthetics.
2004,
Pubmed
Sewell,
A comparison of the molecular bases for N-methyl-D-aspartate-receptor inhibition versus immobilizing activities of volatile aromatic anesthetics.
2009,
Pubmed
,
Xenbase
Shanmugasundararaj,
Carboetomidate: an analog of etomidate that interacts weakly with 11β-hydroxylase.
2013,
Pubmed
Stewart,
Mutations at beta N265 in γ-aminobutyric acid type A receptors alter both binding affinity and efficacy of potent anesthetics.
2014,
Pubmed
,
Xenbase
Tomlin,
Stereoselective effects of etomidate optical isomers on gamma-aminobutyric acid type A receptors and animals.
1998,
Pubmed
Tomlin,
Preparation of barbiturate optical isomers and their effects on GABA(A) receptors.
1999,
Pubmed
Waud,
On biological assays involving quantal responses.
1972,
Pubmed
